New molecular entity.
- Published in:
- Formulary, 2008, v. 43, n. 1, p. 10
- Publication type:
- Article
Works matching DE "BIOMARIN Pharmaceutical Inc."
Results: 21
1
2
NEW PRODUCTS.
- Published in:
- 2006
- Publication type:
- Product Review
3
Laronidase.
- Published in:
- BioDrugs, 2002, v. 16, n. 4, p. 316, doi. 10.2165/00063030-200216040-00009
- Publication type:
- Article
4
Biomedical briefing.
- Published in:
- Nature Medicine, 2014, v. 20, n. 3, p. 226, doi. 10.1038/nm0314-226
- Publication type:
- Article
5
BioMarin nabs first paediatric priority review voucher.
- Published in:
- Nature Reviews Drug Discovery, 2014, v. 13, n. 4, p. 247, doi. 10.1038/nrd4305
- Publication type:
- Article
6
Market watch: Upcoming market catalysts in Q1 2014.
- Published in:
- Nature Reviews Drug Discovery, 2014, v. 13, n. 1, p. 11, doi. 10.1038/nrd4206
- By:
- Publication type:
- Article
7
Trial watch: Enzyme replacement success in Phase III trial for rare metabolic disorder.
- Published in:
- Nature Reviews Drug Discovery, 2013, v. 12, n. 1, p. 12, doi. 10.1038/nrd3929
- By:
- Publication type:
- Article
8
Phase II clinical trials of PEG-PAL are initiated for treatment of phenylketonuria.
- Published in:
- Expert Review of Endocrinology & Metabolism, 2009, v. 4, n. 6, p. 533, doi. 10.1586/EEM.09.53
- Publication type:
- Article
9
Hope. The Power for the Rare Disease Journey.
- Published in:
- Applied Clinical Trials, 2018, v. 27, n. 6, p. 3
- By:
- Publication type:
- Article
10
BioMarin moves into muscular dystrophy with acquisition.
- Published in:
- Nature Biotechnology, 2015, v. 33, n. 1, p. 4, doi. 10.1038/nbt0115-4a
- Publication type:
- Article
11
The price of priority review: $67.5 million.
- Published in:
- Nature Biotechnology, 2014, v. 32, n. 10, p. 973, doi. 10.1038/nbt1014-973
- By:
- Publication type:
- Article
12
PARP inhibitors' revival.
- Published in:
- Nature Biotechnology, 2014, v. 32, n. 2, p. 115, doi. 10.1038/nbt0214-115b
- By:
- Publication type:
- Article
13
The rarest of bounties.
- Published in:
- Nature Biotechnology, 2013, v. 31, n. 8, p. 696, doi. 10.1038/nbt.2649
- By:
- Publication type:
- Article
14
People.
- Published in:
- Nature Biotechnology, 2012, v. 30, n. 10, p. 1008, doi. 10.1038/nbt.2397
- Publication type:
- Article
15
Diagnostic journey and impact of enzyme replacement therapy for mucopolysaccharidosis IVA: a sibling control study.
- Published in:
- 2020
- By:
- Publication type:
- journal article
16
First drug approved for treatment of phenylketonuria.
- Published in:
- American Journal of Health-System Pharmacy, 2008, v. 65, n. 2, p. 100, doi. 10.2146/news080005
- By:
- Publication type:
- Article
17
Companies, technology & environment.
- Published in:
- Chemistry & Industry, 2011, n. 14, p. 11
- By:
- Publication type:
- Article
18
New Market launched.
- Published in:
- Nature Biotechnology, 1999, v. 17, n. 8, p. 737, doi. 10.1038/11636
- By:
- Publication type:
- Article
19
Galsulfase.
- Published in:
- Drugs in R&D, 2005, v. 6, n. 5, p. 312, doi. 10.2165/00126839-200506050-00008
- Publication type:
- Article
20
Items of Interest.
- Published in:
- Pediatric Nursing, 2008, v. 34, n. 2, p. 181
- By:
- Publication type:
- Article
21
New drugs and dosage forms.
- Published in:
- American Journal of Health-System Pharmacy, 2005, v. 62, n. 14, p. 1437
- Publication type:
- Article